~~said agents combined~~ with a particulate carrier.

2. (Amended) The **preparation** [process] of claim 1, wherein [characterised in that] said particulate carrier comprises at least one of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a Large Porous Particle preparation, or a laser-pulse polymer coated molecule preparation.

3. (Amended) The **preparation** [process according to claim 1 or 2] ~~of claim 1~~, wherein **[characterised in that]** at least the greatest part of said agent is encapsulated inside the carrier, especially a liposome or microsphere carrier.

4. (Amended) The **preparation** [process of any one of claims 1 to 3] of claim 1, wherein **[characterised in that]** the antiseptic agent is selected from oxygen-releasing compounds, and halogen-releasing compounds, metal compounds, such as silver and mercury compounds; organic disinfectants including inter alia formaldehyde-releasing compounds, alcohols, phenols, including alkyl**phenols,** [- and] arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

5. (Amended) The **preparation** [process according to] of claim 4, wherein **[characterised in that]** the antiseptic agent is selected from the group comprising metal compounds such as

mercury compounds, phenol derivatives such as thymol, eugenol and hexachlorophene, iodine and iodine complexes.

6. (Amended) The **preparation of** **[process according to]** claim 5, **wherein** **[characterised in that]** the antiseptic agent is povidone iodine.

7. (Amended) The **preparation** **[process according to any one of claims 1 to 6] of claim 1, wherein** **[characterised in that]** the wound-healing promoting agent is selected from agents promoting granulation and epithelization such as dexpanthenol, allantoines, azulenes, tannines, compounds from the vitamin B series, or similarly acting agents.

8. (Amended) The **preparation** **[process according to any one of the preceding claims] of claim 1, wherein** **[characterised in that]** the preparation contains at least one antiseptic and at least one wound-healing promoting agent.

9. (Amended) The **preparation** **[process according to any one of the preceding claims] of claim 1, wherein** **[characterized in that]** the carrier particles, **[especially liposomes,]** have a substantially uniform size in the range between about 1 **μm** and about 50 μm**[, preferably in the range between about 1 and about 30 μm]**.

10. (Amended) The **preparation of claim 9** **[process according to claim 9] wherein,**

[characterised in that] the carrier particles, **[especially liposomes,]** have a substantially uniform size in the range between 20 **μm** and 30 ~~μm~~ diameter for application to the trachea**[, in the range between about 10 and 20 μm diameter for application to the bronchi and between about 1 and 6 μm, especially between 2 and 5 μm, diameter for application to the alveoli]**.

11. (Amended) The **preparation** [process according to any of the preceding claims] **of claim 1, wherein [characterised in that]** the carrier**[, especially liposome, preparation]** releases the agent over an extended time period**[, preferably an extended time period of several hours duration]**.

12. (Amended) The **preparation of [process according to]** claim 11, **wherein [characterised in that]** the carrier**[, especially liposome, preparation]** releases the agent at approximately the same release rate over the release time period.

13. (Amended) The **preparation of** [process according to any one of the preceding claims] **claim 1, wherein [characterised in that]** the preparation additionally comprises at least one anesthetically active agent.

14. (Amended) The **preparation** [process according to any one of the preceding claims] **of claim 1, wherein [characterized in that]** the preparation contains additives and adjuvants **[such as] comprising** conserving agents, antioxidants and consistency-forming additives.

15. (Amended) The **preparation [process according to any one of claims 1 to 14] ~~of claim~~ 1, wherein** the preparation **[being] comprises ~~a~~** suitable form for administration via the lower respiratory tract comprising **[the] an ~~a~~**ctive-agent loaded carrier, **wherein the carrier is [especially]** in the ~~f~~orm of liposomes, **[preferably]** in the form of an aerosol, **or [especially]** in the from of a powder aerosol.

16. (Amended) The **preparation [process according to any one of claims 1 to 14] of claim 1, wherein** the preparation **[being in the form of] comprises** a compacted solid medicament reservoir, **[preferably]** a ring-tablet, **[more preferably]** a gelatin capsule, a powder, a spray, an emulsion, a dispersion, a suspension or a solution containing the carrier and agent or agents in a pharmaceutically acceptable solid or liquid formulation, which is suitable for the generation of inhalable particles.

17. (Amended) The **preparation [process according to any one of the preceding claims] of claim 1, [being in] comprising** a suitable form for administration via the lower respiratory tract, which comprises:

(a) liposomes comprising a pharmaceutically acceptable liposome membrane forming substance; and

(b) a 0.1 to 2% PVP iodine solution (at approximately 10% available iodine in the PVP iodine complex) at least most of which is encapsulated by said liposome membranes,

wherein the liposomes are of substantially uniform size between about 1 **μm** and about 50

μm, and**[, in case,]** the formulation additionally comprises customary additives, adjuvants and auxiliary substances of a pharmaceutical solution or dispersion formulation.

18. (Amended) The **preparation** **[process]** according to claim 17, characterised in that the liposomes are of a substantially uniform size, in the range between 20 **μm** and 30 μm diameter for application to the trachea**[, in the range between about 10 and 20 μm diameter for application to the bronchi and between about 1 and 6 μm, especially between 2 and 5 μm, diameter for application to the alveoli]**.

19. (Amended) The **preparation** [process according to any one of claims 1 to 18] **of claim 1**, wherein the preparation is suited for the treatment of infectious diseases or alleviation of diseases such as HIV infections which are accompanied by opportunistic infections or a suppressed immune system.

20. (Amended) The **preparation** **[process according to any one of claims 1 to 18]** **of claim 1**, wherein the preparation is suited for the treatment of acute **bronchitis, [and/or]** chronic bronchitis, pneumonia, bronchiectasia, cystic fibrosis, diphtheria **[and/or]** **or** tuberculosis.

21. (Amended) The **preparation** **[process according to any one of claims 1 to 20]** **of claim 1**, wherein the preparation is suited for functional and cosmetic tissue remodeling and repair treatments.

22. (Amended) A method of preventing or treating infections of the human or animal lower respiratory tract **comprising:[, by]** applying, to said tract, a pharmaceutical preparation comprising at least one antiseptic agent **[and/or] or** wound-healing promoting agent, **[said agent being]** combined with a particulate carrier in said preparation.

23. (Amended) A method of functional and cosmetic tissue remodeling and repair in the human or animal lower respiratory tract**[, by] comprising:** applying, to said tract, a pharmaceutical preparation comprising at least one anti-inflammatory, **[especially]** antiseptic **[and/or] or** wound-healing promoting agent combined with a **[particulatar] particulate** carrier.

26. (Amended) The method of claim 23, wherein the anti-inflammatory agent is selected from antiseptic agents, antibiotics, corticosteroids **[and] or** wound-healing promoting agents.

27. (Amended) The method of claim 22 or 23, wherein the antiseptic agent is selected from oxygen-**releasing compounds** and halogen-releasing compounds; metal compounds, such as silver **compounds** and mercury compounds; organic disinfectants including inter alia formaldehyde-releasing compounds, alcohols, phenols including alkyl**phenyols[- and]** arylphenols as well as halogenated phenols, quinolines and acridines, hexahydropyrimidines, quaternary ammonium compounds and iminium salts, and guanidines.

~~32. (Amended) The method of claim 22 or 23, wherein the carrier particles[, especially~~

liposomes,] have a substantially uniform size in the range between about 1 μm and about 50 μm[, **preferably in the range about 1 μm and about 30 μm**].

33. (Amended) The method according to claim 32, wherein the carrier particles[, **especially liposomes,**] have a substantially uniform size in the range between 20 μm and 30 μm diameter for application to the trachea[, **in the range between about 10 and 20 μm diameter for application to the bronchi and between about 1 and 6 μm diameter, especially between 2 and 5 μm, for application to the alveoli**].

34. (Amended) The method of claim 22 or 23, wherein that the carrier[, **especially liposome, preparation**] releases the agent over an extended time period[, **preferably an extended time period of several hours duration**].

35. (Amended) The method of claim 22 or 23, wherein the carrier[, **especially liposome, preparation**] releases the agent at approximately the same release rate over the release time period.

38. (Amended) The method of claim 22 or 23, **wherein** the preparation [being in] **comprises** a suitable form for administration via the lower respiratory tract, comprising the active-agent loaded carrier, [**especially**] in the form of liposomes, [**preferably**] in the form of an aerosol, [**especially**] **or** in the form of a powder aerosol.

39. (Amended) The method of claim 22 or 23, **wherein** the preparation **[being in the form of] comprises** a compacted solid medicament reservoir, **[preferably]** a ring-tablet, **[more preferably]** a gelatine capsule, a powder, a spray, an emulsion, a dispersion, a suspension or a solution containing the carrier and agent or agents in a pharmaceutically acceptable solid or liquid formulation, which is suitable for the generation of inhalable particles.

41. (Amended) The method of claim 22 or 23, wherein the liposomes are of a substantially uniform size in the range between 20 **μm** and 30 μm diameter for application to the trachea **[, in the range between about 10 and 20 μm diameter for application to the bronchi and between about 1 and 6 μm, especially between 2 and 5 μm, diameter for application to the alveoli]**.

43. (Amended) The method of claim 22 or 23, wherein the preparation is suited for the treatment of acute **bronchitis, [and/or] or** chronic bronchitis, pneumonia, bronchiectasia, cystic fibrosis, diphtheria **[and/or] or** tuberculosis.

Please **add** the new claims as follows:

--44. (New) The preparation according to claim 9, wherein the carrier particles, have a substantially uniform size in the range between about 1 μm about 30 μm..--

--45. (New) The preparation according to claim 10, wherein, the carrier particles, have a

substantially uniform size in the range between about 10 μm and 20 μm diameter for application to the bronchi.--

42 --46. (New) The preparation according to claim 10, wherein, the carrier particles, have a substantially uniform size in the range between about 1 μm and 6 μm for application to the alveoli.--

43 --47. (New) The preparation according to claim 10, wherein, the carrier particles, have a substantially uniform size in the range between about 2 μm and 5 μm for application to the alveoli.--

44 --48. (New) The preparation according to claim 17, wherein the liposomes are of a substantially uniform size, in the range between 10 μm and 20 μm diameter for application to the bronchi.--

45 --49. (New) The preparation according to claim 17, wherein the liposomes are of a substantially uniform size, in the range between 1 μm and 6 μm diameter for application to the alveoli.--

46 --50. (New) The preparation according to claim 17, wherein the liposomes are of a substantially uniform size, in the range between 2 μm and 5 μm diameter for application to the alveoli.-

47 --51. (New) The method of claim 22 or 23, wherein the carrier particles have a substantially uniform size in the range between about 1 **μm** and about 30 μm.--

48 --52. (New) The method according to claim 32, wherein the carrier particles have a substantially uniform size in the range between 10 μm and 20 μm diameter for application to the bronchi.--

49 --53. (New) The method according to claim 32, wherein the carrier particles have a substantially uniform size in the range between 1 μm and 6 μm diameter for application to the alveoli.--

50 --54. (New) The method according to claim 32, wherein the carrier particles have a substantially uniform size in the range between 2 μm and 5 μm diameter for application to the alveoli.--

51 -- 55. (New) The method of claim 22 or 23, wherein the liposomes are of a substantially uniform size in the range between 10 μm and 20 μm diameter for application to the bronchi.--

52 -- 56. (New) The method of claim 55, wherein the liposomes are of a substantially uniform size in the range between 1 μm and 6 μm diameter for application to the alveoli.--

53 --57. (New) The method of claim 56, wherein the liposomes are of a substantially uniform size